Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (448)	4/11/2003 3:38:59 AM
From: nigel bates	Read Replies (1) of 469

Possibly the MEDX deal is too big of a potential cash liability for any more opportunist bidders to emerge with a higher offer ? Jan 9 2002 ...Oxford GlycoSciences Plc, Medarex (Nasdaq: MEDX - news) and Genmab A/S today announced a new comprehensive and targeted approach intended to create an array of novel medical products for breast cancer. This initiative builds on the alliance announced in September 2000 and brings together breast cancer targets that have been discovered through OGS' proteomics platform with Medarex and Genmab's combined strengths in creating and developing immunological products. The first product in the program, a fully human therapeutic antibody, is expected to enter clinical trials in about one year. It targets heparanase I, an enzyme involved in the growth and spread of many cancers, including breast cancer... ...Recently OGS and Medarex agreed to change the heparanase I program from a fee for service program to a joint program under this collaboration on terms which were not disclosed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next